Category Archives: Stem Cell Clinic


Making Babies, No Sex Necessary – The Atlantic

In the future, when a couple wants to reproduce, they will not make a baby in a bed or in the backseat or a car, or under a Keep Off the Grass sign, says Henry Greely, the director of the Center for Law and the Biosciences at Stanford Law School.

Instead, they will go to a clinic. Using stem cells from the couples skin or other non-reproductive organs, scientists will be able to make eggs and sperm, which will be combined into embryos. Each of those embryos will have its own gene sequence, Greely says. The parents will be asked: What do you want to know about these embryos? And theyll be told.

Twenty or 30 years from now, parents will be able to screen their potential kids for genetic abnormalities, pre-disposal to disease, sex, and even cosmetic features like hair, eye, and skin color, Greely claims. The new way of baby-making will save women the pain of going through fertility treatments, he says, and it will prevent disease, save health-care costs, and give non-traditional families more chances to have children. If this reproductive future comes to pass, it will also come with a tangle of moral, legal, and medical questionsones that wont be easy to resolve, despite what Greely may think.

When Greely tells people about his theorywhich is the subject of his 2016 book, The End of Sex and the Future of Human Reproductionthey tend to say, This is Gattica, or this is Brave New World, he said during an interview with the New York Times reporter Carl Zimmer on Monday at the Aspen Ideas Festival, which is co-hosted by the Aspen Institute and The Atlantic. Greely is skeptical of this argument. This is not designer babies. This is not super babies. This is selecting embryos, he said.

Greely gets some of his confidence from the limits of science. Geneticists likely wont be able to predict kids behavioral traits, he said, like their aptitude for math or agility on a sports field. But they may be able to anticipate some traits, like intelligence, in broad strokes. Being able to tell parents that this embryo has a 60 percent chance of being in the top half [of their school class], this embryo has a 13 percent chance of being in the top 10 percentI think thats really possible, he said.

Scientists have been screening embryos using a process called preimplantation genetic diagnosis, or PGD, for two and half decades, Greely said. This allows for the detection of some genetic diseases, as well as determining the sex of the embryo. Up until now, it has been expensive and arduous, but with new technologyincluding the expanded use of stem cellsit will become easy, he said. The people most likely to lead the way on easy PGD are those with fertility trouble, he argues, or those who cant have their own biological kids, including same-sex couples. For these people, the process seems to be a clear potential win: Once hopeless, they may soon be able to have biological children of their own.

But if the process does indeed advance in the way Greely predicts, it will come with big ethical challenges. Safety is a big issue, he said. Coercion is a big issue: Will you be forced to do this? No matter how easy PGD becomes, it will always be expensive, meaning that babies from rich families would gain even more advantages over other people before they leave the womb. The procedure also challenges the disability-rights movement, Greely pointed out: It implicitly suggests that some traits, and thus some people, are preferable to others.

Theres very little about our modern lives that a God from 3000 years ago would have expected.

Some critics may also claim this process is against Gods will, Greely added. I dont have a lot of confidence in the intellectual strength of that argument, but I think it has a lot of visceral support.

Despite Greelys skepticism, this seems to be the greatest potential objection to a world of skin-cell babies and intensive genetic screening: It assumes that the creation of life is a matter of pipettes and petri dishes, not something greater. While the widespread use of contraceptives has largely divorced sex from procreation, this process would represent the final severing. As Greely pointed out, the very meaning of sex would change. Most people have sex and it doesnt result in a baby, he said. They do it because they like it. They do it as a token of love. They do it because theyre forced to. They do it to make money. Pleasure, ultimately, will be a main driver of sex, he added.

For the many peoplereligious or notwho believe that life is not ultimately a matter of science, the world of easy PGD may seem disorienting, even morally disturbing. But Greely didnt think religious or moral arguments could persuade someone like him, or society more broadly, that easy PGD isnt a good idea.

If you, coming from a Catholic background, try to convince me, coming from a non-Catholic background ... that wouldnt work for me, he said. I need a more intellectual argument than one based on my faith or the tablets brought down from the mountain for me say this. Theres very little about our modern lives thats natural or what a God from 3000 years ago would have expected or wanted, including all of modern medicine.

As head-spinning as these theoretical ethical challenges are, perhaps easy PGD wont be as common as Greely thinks. After all, he joked, were never going to get rid of teenagers in the back seat of a car.

Follow this link:
Making Babies, No Sex Necessary - The Atlantic

Stem Cell Stem Cell Treatments by Clinic 42

Home Version 10 topcatt 2016-10-03T01:15:08+00:00

Stem cells are tiny progenitor cells. They have the potential to recognise tissue injury and repair injured cells. In the right environment, these stem cells can change (differentiate) into bone, cartilage, muscle, fat, collagen, neural tissue, blood vessels and even some organs. Stem cells may also affect healing by secreting special chemical messengers that repair damaged tissue. Adult stem cells appear to be particularly effective in improving painful joints, repairing cartilage and ligaments and even painful conditions along the spine. There are many clinical trials with stem cells going on right now which suggest a very broad and exciting potential for Stem Cells in Advancing Medicine. At Clinic 42, we assess each case on its merits as to suitability for treatment. Please use our online application formto submit an application for selection to undergo this advanced new therapy, or contact usto learn more.

Clinic 42 is an Advanced Cosmetic Medical Clinic based in Epsom, Auckland. We provide the most Advanced and Scientifically Proven Treatments Delivered Under the Careful Guidance of Our Doctors.

Read more:
Stem Cell Stem Cell Treatments by Clinic 42

Powerful boost for bad skin days – Inquirer.net

These drips dont only improve your appearance.

Aivee (IV) Drips are safe, injectable treatments that restore the skins energy, vitality and glow fast because they go directly into the vein. The rains are a welcome respite, even as the wet season still feels hot as summer. But it also means we are susceptible to colds and bad skin days.

Oral medicine and green smoothies can only do so much to our bodies. What busy bees really need is a rapid, powerful boost in our systems that can get us looking and feeling great again in no time.

Its good to know the Aivee Clinic (my trusted skin superhero) is offering Aivee (IV) Dripssafe, injectable treatments that help restore energy, vitality and glow faster because they go directly into the vein. Administered in clinics, these drips dont only improve your appearance. Youll be surprised, like I was, by how varied the infusions are.

Revive Drip (Immune Boost) is a great pick-me-up after a long, stressful day at work. Infused with vitamin B complex, vitamin C, glutathione and other minerals, this antioxidant solution restores balance in the body and promotes skin hydration as it eliminates traces of fatigue fast. It isnt nicknamed the ultimate hangover cure for nothing.

Platinum flaunts a mix of vitamins, antioxidants, coenzyme Q10, minerals and other antiaging extracts best for those who seek a renewed glow reminiscent of their youth. This drip is a powerful antiwrinkle solution that helps boost energy and speed up skin recovery.

Brighter skin

For those who want brighter, more luminous skin without avoiding the sun, Glow (Frosty White) detoxifies with its blend of vitamin C and glutathione. The antioxidants in this mix also aid the immune system, taking this a notch above the usual whitening solution.

Athletes can also get a dose of drips fit for their lifestyle. PowerBoost is best for restoring physical performance with a mixture of magnesium, B-complex vitamins and glutathione.

ReShape is a great blend for weight-watchers who hope to stay in perfect shape with a drip infused with vitamins, slimming L-carnitine, and other potent fat-burners and antioxidants. Its an effective way to complement your exercise, burn fat and help keep the body healthy.

Finding light

If youre looking to reduce inflammation, speed up wound healing, or simply improve your health and wellbeing, the state-of-the-art Aivee Light Therapy can do wonders for your physical state.

Its latest Intravenous Light Therapy treatment is best for inflammation abatement, pathogen deactivation, bloodstream cleansing and pain reduction. This is highly recommended for immune system modulation, cell regeneration and neuron repair.

It also increases stem cell proliferation, enhances stem cell survivability and stem cell differentiation.

The Aivee Clinic is at Bonifacio Global City, SM Mega Fashion Hall and Alabang. Call 5731420, 0917-7283838; visit http://www.aivee.ph.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

See the original post here:
Powerful boost for bad skin days - Inquirer.net

Here’s Why US Stem Cell Inc (OTCMKTS:USRM) Shares Just … – The Oracle Dispatch

US Stem Cell Inc (OTCMKTS:USRM) had been looking promising, in gear, and in control of one of the more promising narratives bouncing around on the OTC in recent months following the successful extrication from some legal issues a few months ago. However, that narrative was powerfully dependent on one critical piece of the puzzle a fact which became clear in the stocks reaction to the companys press release on Monday morning of this week.

Couched in the clothes of a message about expansion in its stem cell treatment centers and clinics, the company dropped the bomb that it is giving up on its strategy of obtaining Regenerative Medicine Advanced Therapy (RMAT) Designation from the FDA for its Myocell product. We got an update from the company a couple months ago that it was awaiting a decision from the FDA on this through its MARVEL trial. One can imagine that the market takes Mondays press release as an indication that the FDA provided the company with a sense that there was no point in staying with the application process, for one reason or another.

US Stem Cell Inc (OTCMKTS:USRM) bills itself as a company committed to the development of effective cell technologies to treat a variety of diseases and injuries. By harnessing the bodys own healing potential, we may be able to reverse damaged tissue to normal function.

U.S. Stem Cells discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.

USRM is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases. It is our belief that the unique qualities within the various cell types make them more advantageous to treat a particular disease.

According to company materials, US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

You can find outwhen $USRM stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

As noted above, USRM shares tanked on Monday in response to the companys indication that hope for an RMAT designation from the FDA was ill-placed. Weve witnessed just shy of -50% ripped out of prices for shareholders of the name during the trailing week. Whats more, the listing has seen interest climb, with an increase in recent trading volume of 63% beyond what we have been seeing over the larger time frame.

As also noted, the company did include an announcement of a strategic expansion of its treatment clinic approach. Specifically, the company announced an aggressive plan to expand an additional 12 stem cell treatment centers and clinics in the US.

In the release, the company further clarified its new reality once again: To be clear, U.S. Stem Cell will focus on our revenue generating programs that are treating patients NOWwhich have successfully helped over 7000 patients thus far. Our company was founded in 1999 and has completed more clinical treatments (for both humans and animals) than any other regenerative medicine company in the world. In addition to our efforts at US Stem Cell Training and VetBiologics, our focus will be expanding and opening additional clinics throughout the U.S. to offer these cutting-edge technologies to more patients.

At this time, carrying a capital value in the market of $13.7M, USRM has a store ($619K) of cash on the books, which is balanced by about $3.3M in total current liabilities. One should also note that debt has been growing over recent quarters. USRM is pulling in trailing 12-month revenues of $3.5M. In addition, the company is seeing major top line growth, with y/y quarterly revenues growing at 62.5%. We will update the story again soon as further details emerge. For continuing coverage on shares of $USRM stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

Read the original post:
Here's Why US Stem Cell Inc (OTCMKTS:USRM) Shares Just ... - The Oracle Dispatch

GE and the Mayo Clinic back software to bring cancer-fighting gene … – TechCrunch

Behind the incredible process of developing targeted gene therapies to fight diseases like cancer lies an incredibly mundane problem that prevents these treatments from getting to patients paperwork and procedures.

While $5.7 billion was invested in companies developing cellular and genetic therapies, and with 800 clinical trials initiated worldwide and the first two CAR-T cell therapies expected to launch into market later this year, businesses still saythe ability to get these treatments to patients is limited by paperwork, supply chain management, and last mile delivery.

So GE (through its GE Ventures arm), the Mayo Clinic (through Mayo Clinic Ventures) and the venture investment firm DFJ have invested $13.75 million to back Vineti a software platform the companies are billing as a solution to gene therapys supply chain problem.

Its only the sixth company to have actually been built by GEs internal business team and spun out by the conglomerates venture arm.

According to company co-founder and former GE Ventures managing director Amy DuRoss, the process for developing and managing gene therapies is critical to the success of the treatment.

Amy DuRoss, chief executive at Vineti

To that end, Vinetis software tracks logistics, manufacturing and clinical data to improve treatments and drive down the cost of these therapies (which are mainly only accessible to those people with the very best health plans).

The startups technology was actually born out of necessity (always the mother of invention) and came from conversations that GE was having with a large, undisclosed customer.

A pharma company that is a regular client of GE Healthcare said we are solving late stage cancer and we want to take this commercial but we have not got the technology that can ensure that we can scale out these technologies in the commercial phase, DuRoss told me.

GEs healthcare business then took the problem to the companys venture investment and new business arm and began the development process of building a business.

In addition to DuRoss, who has been a luminary in the life sciences field since she helped with the push to get stem cell research approved in California; Vineti has a murderers row of leading healthcare talent.

Chief strategy officer Heidi Hagen, was the former SVP of Operations for cell immunotherapy pioneer Dendreon; chief technology officer Razmik Abnous was the chief technology officer at the healthcare data management juggernaut Documentum; and Malek Faham, the companys chief science officer, literally worked on some of the foundational science for gene therapies.

While the companys technology could have applications for a number of different treatments, and be used for several kinds of therapies, the focus, for now, is on cancer.

Cancer is a bullseye, says DuRoss. It is arguably the biggest cause of human suffering [and] there are treatments already in phase three, that if brought to market effectively could mark a turning point in medicines battle against the deadly disease, she said.

We see an opportunity as data accrues to the system over time for a use case in predicting therapy based on outcome data but were not making these claims today, said DuRoss.

Mayo Ventures had been working with GE for two years from the initial concept to the close of this new round of financing for Vineti. Its one of only 15 companies that the Clinic has backed since the formation of Mayo Clinic Ventures, and according to Andy Danielsen, the vice chair of Mayo Clinic Ventures.

One thing with Vineti that we liked is that we have a commitment to cell and gene therapies at Mayo, said Danielsen, so the interests were aligned. Vineti will make the gene and cell therapy production process more efficient and as a result, less costly. Its all part of the equation of making these therapies more affordable and opening them up to a greater number of people.

Therapy supply chain

External ordering pages

Product tracking

Therapy scheduling

Identity verification

The rest is here:
GE and the Mayo Clinic back software to bring cancer-fighting gene ... - TechCrunch

Two Notable Announcements in a Week for US Stem Cell Inc … – Street Register

Weve talked about US Stem Cell Inc (OTCMKTS:USRM) quite a bit here on Street Register in the past, and we wanted to swing back around and catch it again today on the heels of an important press release.

In fact, there have been two notable announcements in just the past week, one of which referring to aggressive clinical expansion plans, and the other, to accolades received by a member of USRM management.

Starting with the new news and working our way back, US Stem Cell Inc (OTCMKTS:USRM) has just announced an aggressive plan to expand an additional 12 stem cell treatment centers and clinics in the US. U.S. Stem Cell has been in discussions with the FDA regarding Regenerative Medicine Advanced Therapy (RMAT) Designation for the Myocell product and at this time, the company has decided not to further invest in RMAT Designation and instead invest and focus on our in-clinic therapies for patients.

According to the 21st Century Cures Act, within one year of enactment, the FDA must issue draft guidance clarifying how the FDA will evaluate devices used in the recovery, isolation, or delivery of regenerative advanced therapies. Until this guidance document is published, it is unclear how this regulation will affect the MyoCell program. Until then, U.S. Stem Cell will focus on opening new clinics around the country to better serve patients in need.

In addition to the original Sunrise clinic (that has successfully treated hundreds of patients and generated over $2m in revenues in the past 12 months alone), recent clinic openings include Miami and Palm Beach, Florida. Upcoming openings include Dallas, Texas (thanks in part to the early adoption of patient rights by the State of Texas), Chicago, Atlanta, and Denver as well as other clinics in the northeast and the west coast.

To be clear, U.S. Stem Cell will focus on revenue generating programs that are treating patients NOWwhich have successfully helped over 7000 patients thus far. The company was founded in 1999 and has completed more clinical treatments (for both humans and animals) than any other regenerative medicine company in the world. In addition to efforts at US Stem Cell Training and VetBiologics, the companys focus will be expanding and opening additional clinics throughout the U.S. to offer these cutting-edge technologies to more patients. (Source: Accesswire via OTC Disclosure & News Service)

We also mentioned another bit of press concerning a member of the USRM management team. A scientific paper about intramyocardial implantation co-authored by Kristin Comella, Chief Science Officer at USRM, has been recognized as one of the most influential articles of 2016 for the Journal of Translational Medicine, according to Altmetric.com.

Comella is a world-renowned expert on regenerative medicine with a focus on adipose derived stem cells. She was named number 24 on Terrapins list of the Top 50 Global Stem Cell Influencers and number 1 on the Academy of Regenerative Practices list of Top 10 Stem Cell Innovators. Comella has pioneered stem cell therapies from various sources including cord blood, bone marrow, muscle, and adipose. She led the team that gained the first ever FDA approval for a clinical trial using a combined cell and gene therapy product in the heart. (Source: Accesswire via OTC Disclosure & News Service)

In terms of USRM stock itself, it has actually gotten hammered recently, and there seems a very good chance of seeing a rebound play at some point so we will want to keep our eyes peeled for that. Want to follow along USRMs progress with us? Just stay locked to Street Register for updates, and well deliver important developments on USRM as they unfold. In the meantime, if youve yet to sign up for our 100% free newsletter, do so now! Just enter your active email address into the box below and submit!

Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in USRM stock, short or long.

Read the rest here:
Two Notable Announcements in a Week for US Stem Cell Inc ... - Street Register

Stem Cell Therapy for Glaucoma – Are We There Yet? – Newswise (press release)

Newswise There is great interest among glaucoma patients, scientists and doctors alike, in discovering regenerative therapies for the optic nerve and translating them from the laboratory to the clinic and stem cell therapy is one of several promising approaches being studied.

Recently, we heard from a glaucoma patient who enrolled in a patient-funded trial in which the person paid $20,000 and received stem cell injections around one eye. Patient-funded trials are studies in which patients pay to participate. This approach was developed because clinical trials are expensive and funding from traditional sources (such as the NIH, pharmaceutical companies, or private foundations) is decreasing.

Although patient-funded research would appear superficially to provide an avenue for patients to obtain therapies under investigation, it is controversial for a number of reasons, both scientific and ethical. Scientific considerations are deeply concerning: the gold standard for evaluating an experimental treatment is a randomized clinical trial in which participants are randomly allocated to the experimental treatment group or a control group that may not receive any treatment (placebo-controlled study), or may receive standard, approved therapies. Usually, study patients and doctors are both unaware of who receives which treatment and this study design minimizes bias towards a particular treatment.

In contrast, patient-funded trials do not have a control group, since it is extremely unlikely that patients would pay when there is a possibility of not receiving the experimental treatment. A control group is very important to determine if an experimental treatment really has an effect and also to compare the efficacy and risks of the experimental treatment versus other treatments. Although it is common in an early, phase 1 trial to treat perhaps the first 3-12 patients in an open-label, non-randomized study, by phase 2 trials, a randomized, masked design is ideal.

Even more concerning are the ethical considerations. These include disparity in access to the treatment, and risk of exploitation of vulnerable patients who have exhausted all treatment options and may be willing to undergo an unproven treatment at any cost. In addition, a reported lack of proper oversight and monitoring for patient-funded trials implies the possibility that these may be thinly-veiled attempts to make money by the treating clinic or physician before proper FDA approval of new treatment methods.

Since a gold standard research study is not always feasible, decisions regarding the benefits and risks of a particular treatment may have to be made with the evidence at hand. Given these considerations, we consulted Dr. Jeffrey Goldberg regarding stem cell therapy for glaucoma. Dr. Goldberg is a leading expert in therapies to regenerate the optic nerve and is part of the Catalyst for Cure team. His laboratory is developing novel stem cell approaches for glaucoma, and working steadily towards a translational program to bring discoveries out of the laboratory and into human testing once safety and efficacy in pre-clinical models is established.

Q: Dr. Goldberg, how might stem cells be helpful for patients with glaucoma?

A: Stem cells may be helpful for patients with glaucoma in different ways. Stem cells can be turned into trabecular meshwork cells in the front of the eye and transplanted in such a way as to lower eye pressure. This is an interesting approach but is not fundamentally about vision restoration.

For protecting or restoring vision, we really need to talk about stem cells in the back of the eye, at the retina. There, stem cells may have two positive effects. First, early in the disease, they may protect retinal ganglion cells from degenerating providing a neuroprotective effect. Later in the disease when patients have lost considerable numbers of retinal ganglion cells and optic nerve axons, and have thereby lost considerable vision, stem cells may be useful to replace lost ganglion cells and restore the connections from the eye to the brain. This last approachregrowing optic nerve fibers back to the brainhas been the most challenging but its also the most exciting.

What is the current status of research on stem cell therapy for glaucoma?

Our laboratory and a number of other laboratories have made considerable progress on the two main fronts of bringing stem cell therapy to optic nerve restoration for glaucoma. First, we and others have discovered molecular pathways that can be used to coax stem cells to turn into neurons that look and act like real retinal ganglion cells. This will allow us to turn large numbers of stem cells into retinal ganglion cells for cell replacement therapy. Second, we are just beginning to make progress in transplanting retinal ganglion cells into the retina in pre-clinical models, to study their integration into the adult retina, how they respond to light and grow back down the optic nerve to the brain. Together these advances have brought us to an exciting moment in stem cell research for optic nerve restoration in glaucoma.

Are you aware of any studies in which stem cell therapy stabilized or reversed vision loss from glaucoma?

Stem cells have not yet been properly tested in patients with glaucoma to look for their ability to stabilize or reverse vision loss. The careful move from the laboratory to clinical testing is still ahead of us, although with the intellectual energy and resources ready to deploy, such proper testing may not be far off.

If your family member had vision loss from glaucoma, would you recommend stem cell therapy at this time?

I am often asked by my patients if they should sign up for a patient-funded trial for stem cells for glaucoma, and I am in the habit of counseling against this. I am not aware of any properly designed stem cell trials for glaucoma with well-tested cell therapies being moved to human testing at this time, but I do think these will come.

Are there any risks or complications reported with stem cell therapy for glaucoma?

Indeed the risks for undergoing stem cell injections in any trial could be significant. Risks of infection, inflammation, and more severe vision loss will always be present; we are publishing a paper about 3 patients in the U.S. who participated in a patient-funded trial and lost significant vision due to severe inflammation in their eyes called endophthalmitis. These 3 unfortunate patients point to the importance of a cell therapy first undergoing proper testing in pre-clinical models before moving to human testing. Then, with properly designed and sequenced trials, I believe cell therapies can be safely tested in the eye as with the rest of the body. Indeed there are a number of cell therapies for macular degeneration already in human testing with a reassuring safety record thus far.

What type of study would you design for evaluating stem cell therapy with glaucoma?

After demonstrating safety and efficacy of a cell therapy product in pre-clinical models, a small pilot study designed to assess for safety after injection in humans and analysis of the results should be the first step. After this, a move to a randomized trial with a control group and masked observers will be best to assess efficacy in phase 2 and eventually phase 3 trials.

Article by Sunita Radhakrishnan, MD, Jeffrey L. Goldberg, MD, PhD, and Andrew Iwach, MD.

For additional information on this topic, following are links to related articles from the American Academy of Ophthalmology:

Unregulated Stem Cell Treatments Can Be Dangerous [June 6, 2017]

American Academy of Ophthalmology Statement on Stem-Cell Therapy for Treating Eye Disease [March 20, 2017]

Unapproved stem cell treatment blinds 3 patients [March 17, 2017]

Stem Cell Therapy for Eye Disease: What You Need to Know [June 24, 2016]

Intraocular Stem Cell Therapy [June 2016]

Excerpt from:
Stem Cell Therapy for Glaucoma - Are We There Yet? - Newswise (press release)

Dr. Ruben A. Mesa of Arizona’s Mayo Clinic named new director of … – San Antonio Express-News (subscription)


San Antonio Express-News (subscription)
Dr. Ruben A. Mesa of Arizona's Mayo Clinic named new director of ...
San Antonio Express-News (subscription)
Dr. William Henrich, president of UT Health Science Center San Antonio, described Mesa as an international expert in myeloproliferative neoplasms, or MPNs, ...

and more »

Read the original here:
Dr. Ruben A. Mesa of Arizona's Mayo Clinic named new director of ... - San Antonio Express-News (subscription)

Looking Back: June 9, 2017 – Fairbanks Daily News-Miner

10 YEARS AGO

June 9, 2007 Alaskas congressional delegation continues to support legislation that would give the federal government more opportunities to fund embryonic stem cell research.

Rep. Don Young voted in favor of the Stem Cell Research Enhancement Act of 2007 on Thursday, which would make federal funds available to research projects using excess embryonic stem cells that have been donated to an in vitro clinic, and would otherwise be discarded.

The House voted 247-176 in favor of the bill, which has been sent to President Bush.

25 YEARS AGO

June 9, 1992 Fairbanks Mayor Wayne Nelsons sweeping four-part plan to cut the costs of city government and generate revenues survived its introduction to the city council Monday.

The council voted unanimously to advance ordinances calling for the closure of the Fairbanks Fire Department, the creation of a city-run lottery, the appointment of a revenue commission and the opening of the citys labor negotiations to the public.

50 YEARS AGO

June 9, 1967 Fairbanks could receive live television programming from communication satellites within 18 months, Alaskas broadcasters were told yesterday.

Maj. Gen. George P. Sampson, USA-Ret., vice president for operations with Communications Satellite Corp., described the rapidly developing future of satellite communication to a luncheon meeting of the Alaska Broadcasters Association here yesterday.

75 YEARSAGO

June 9, 1942 The million miles which Al Jolson has been promising since 1909 to walk for one of his mammys smiles was never closer to an accurate figure today.

At least 900,000 miles, by his own calculation, from the spot where he knows the sun shines best the dynamic song and patter man of stage, screen, and radio strolled the streets of Fairbanks, making mental notes of his first view of life in Alaska while marking time before the first performance of his Keep em Smilin tour of the Territorys Army encampments.

Before most of the men in Uncle Sams new Army were born Al Jolson was already dubbed one of the greatest dominators in the theater. And, years before that, he had shucked off the name he brought with him to the United States from his native Russia as a boy of seven Asa Yoelson and turned his aspirations from that of becoming a cantor.

Read the original here:
Looking Back: June 9, 2017 - Fairbanks Daily News-Miner

Asymmetrex Director Comments on Positive Attributes of Private … – PR Web (press release)

Many more patients are estimated to receive stem cell treatments in private clinics than in clinical trials.

Boston, MA (PRWEB) June 08, 2017

In a new early view article published in the online Journal of Stem Cell Research and Medicine, James L. Sherley, M.D., Ph.D., founder and director of Asymmetrex, LLC, asks the question, Why are patients scared away from private stem cell clinics? (May 6, 2017). Sherley presents a critical assessment of the warnings pronounced by federal agencies and professional organizations, like the National Institutes of Health (NIH) and the International Society for Stem Cell Research (ISSCR), against private clinics providing stem cell treatments. He argues that new treatments in private clinics are, for the most part, not very different than stem cell treatments in clinical trials authorized by the Food and Drug Administration (FDA).

In his comment, Sherley chides the NIH, ISSCR, and alarmist commentators for portraying private stem cell clinics, as a group, as unethical, and even dangerous to patients, without good evidence to support their claims. He provides examples to show that many operational elements of stem cell treatments in private clinics are not unlike FDA-authorized clinical trials. Both stem cell treatment settings have strengths and weaknesses. Sherleys position is that, In their missions to serve patients, the NIHs and ISSCRs efforts would seem to be better spent informing patients how to obtain the best care in either setting. In earlier writings and presentations, he has also urged decision-makers to develop policies for collecting, organizing, and studying stem cell treatment data from private clinics. Since the number of patients treated in private clinics is now estimated to far exceed the number in clinical trials, Sherley has argued that excluding this valuable experience by vilifying it is a tragic loss to stem cell medical research and patients.

A crucial way in which FDA-authorized clinical trials and private stem cell treatment clinics are not different is their past lack of a means to determine the dose and quality of stem cell treatments. In his published comment, Sherley notes that none of the anti-private clinic alarmists acknowledges this deficiency that also impacts the worth of stem cell clinical trials. In fact, this need even limits the quality of some approved stem cell therapies like umbilical cord blood stem cell transplant.

Asymmetrex has recently developed a technological solution for the half century-old problem of specifically counting tissue stem cells. With the companys new technology, it is now possible to determine the dose and quality of therapeutic tissue stem cell preparations. Asymmetrex is positioned to become the certifying agency for the dose and quality of tissue stem cells used in approved treatments and either FDA-authorized clinical trials or private stem cell clinic treatments. Sherley predicts that adoption of this shared certification process will promote a more reasoned assessment of the contributions that private stem cell clinics are and can make to accelerating progress in stem cell medicine.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrexs founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The companys patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrexs focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

Share article on social media or email:

View original post here:
Asymmetrex Director Comments on Positive Attributes of Private ... - PR Web (press release)